Bruker Corporation (BRKR) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $57.29: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 17%; Elevated put/call ratio: 32.44; Below-average business quality.
Bruker develops and distributes high-performance scientific instruments across four segments: BSI BioSpin (NMR/MRI), BSI CALID (mass spec, microbiology diagnostics), BSI NANO (X-ray, microscopy, metrology), and BEST (energy/superconductor). Revenue is internationally distributed... Read more
Sell if holding. Engine safety override at $57.29: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 17%; Elevated put/call ratio: 32.44; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.4/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Bruker Corporation
Latest news
- NEWS Bruker Corp Files Prospectus For Mixed Shelf Offering, Size Not Disclosed — benzinga Jun 12, 2026 neutral
- NEWS Bruker's Microbiology & Infection Diagnostic Division Showcases Expanding Portfolio, Innovations Throughout Microbial Id — benzinga Jun 4, 2026 positive
- NEWS Bruker Launches New Mass Spectrometry Platform For Petroleomics And Sustainable Fuels Research — benzinga Jun 2, 2026 positive
- NEWS Wolfe Research Assumes Bruker at Peer Perform — benzinga Jun 2, 2026 neutral
- NEWS At ASMS, Bruker Launches TimsMRMS System, Focused On Trapped Ion Mobility Separation To Ultra-high-resolution Magnetic R — benzinga Jun 1, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicEurope36%10-K Item 1A: 'Our revenue from operations in Europe represented approximately 36% and 35% of total consolidated revenue for fiscal years 2025 and 2024'
- MEDIUMGeographicAsia Pacific30%10-K Item 1A: 'Our revenue from operations in the Asia Pacific region represented approximately 30% and 29% of total consolidated revenue for fiscal years 2025 and 2024'
Material Events(8-K, last 90d)
- 2026-04-10Item 5.02MEDIUMFalko Busse, President of Bruker BioSpin, agreed to transition duties around May 1, 2026 with employment ending October 31, 2026. Separation agreement provides ~$1,020,351 CHF in severance, pro-rated bonus, and unused vacation. No successor named.SEC filing →
- 2026-04-01Item 5.02LOWThierry L. Bernard (CEO of QIAGEN) appointed to Bruker's Board as Class III director effective April 1, 2026, serving until the 2027 Annual Meeting of Stockholders.SEC filing →
- 2026-02-20Item 5.02LOWDr. Cynthia Friend will not stand for re-election at 2026 Annual Meeting (no disagreement cited). Jack Phillips reclassified from Class III to Class II director effective February 19, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -0.3%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $57.29: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 17%; Elevated put/call ratio: 32.44; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $53.33. Score 4.4/10, moderate confidence.
Take-profit target: $63.25 (+10.3% upside). Prior stop was $53.33. Stop-loss: $53.33.
Target reached (-19.2% upside); Quality below floor (3.8 < 4.0).
Bruker Corporation trades at a P/E of N/A (forward 23.1). TrendMatrix value score: 5.4/10. Verdict: Sell.
22 analysts cover BRKR with a consensus score of 3.9/5. Average price target: $53.
What does Bruker Corporation do?Bruker develops and distributes high-performance scientific instruments across four segments: BSI BioSpin (NMR/MRI),...
Bruker develops and distributes high-performance scientific instruments across four segments: BSI BioSpin (NMR/MRI), BSI CALID (mass spec, microbiology diagnostics), BSI NANO (X-ray, microscopy, metrology), and BEST (energy/superconductor). Revenue is internationally distributed with Europe (~36%), APAC (~30%), and US (~26%) of 2025 revenues; China contributed $475.8M. US academic funding reductions and delayed Chinese government stimulus are cited 2025 headwinds.